A dramatic increase in newborn infants with neonatal abstinence syndrome has been observed and these neonates are frequently treated with complex methadone dosing schemes to control their withdrawal symptoms. Despite its abundant use, hardly any data on the pharmacokinetics (PK) of methadone is available in preterm neonates. Therefore we investigated developmental PK of methadone and evaluated current dosing strategies and possible simplification in this vulnerable population.
A single‐centre open‐label prospective study was performed to collect PK data after a single oral dose of methadone in preterm neonates. A population PK model was built to characterize developmental PK of (R)‐ and (S)‐methadone. Model‐based simulations were performed to identify a simplified dosing strategy to reach and maintain target methadone exposure.
A total of 121 methadone concentrations were collected from 31 preterm neonates. A one‐compartment model with first order absorption and elimination kinetics best described PK data for (R)‐ and (S)‐methadone. Clearance increases with advancing gestational age and differs between R‐ and S‐enantiomer, being slightly higher for the former (0.244
vs0.167 L/h). Preterm neonates reached target exposure after 48 hours with currently used dosing schedules. Output from simulations revealed that target exposures can be achieved with a simplified dosing strategy during the first 4 days of treatment. Conclusion
Methadone clearance in preterm neonates increases with advancing gestational age and its disposition is influenced by its chirality. Simulations that account for developmental PK changes indicate a shorter methadone dosing strategy can maintain target exposure to control withdrawal symptoms.